Pharmaceuticals company Caplin Point Laboratories announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: Revenue from Operation: Rs 435.50 crore, increased by 17.0% compared to Q3FY23. Total Revenue: Rs 452.68 crore, increased by 17.2% compared to Q3FY23. Gross Profit: Rs 245.39 crore, increased by 17.9% compared to Q3FY23. Gross Margin%: 56.3%, increased from 55.9% in Q3FY23. EBITDA: Rs 159.46 crore, increased by 29.1% compared to Q3FY23. EBITDA Margin%: 35.2%, increased from 32.0% in Q3FY23. PBT: Rs 145.41 crore, increased by 30.1% compared to Q3FY23. PBT Margin%: 32.1%, increased from 28.9% in Q3FY23. PAT: Rs 119.82 crore, increased by 23.0% compared to Q3FY23. PAT Margin%: 26.5%, increased from 25.2% in Q3FY23. Consolidated 9MFY24: Revenue from Operation: Rs 1,240.88 crore, increased by 15.2% compared to 9MFY23. Total Revenue: Rs 1,290.53 crore, increased by 15.0% compared to 9MFY23. Gross Profit: Rs 708.07 crore, increased by 19.8% compared to 9MFY23. Gross Margin%: 57.1%, increased from 54.8% in 9MFY23. EBITDA: Rs 455.86 crore, increased by 26.0% compared to 9MFY23. EBITDA Margin%: 35.3%, increased from 32.2% in 9MFY23. PBT: Rs 418.40 crore, increased by 27.8% compared to 9MFY23. PBT Margin%: 32.4%, increased from 29.2% in 9MFY23. PAT: Rs 340.19 crore, increased by 23.4% compared to 9MFY23. PAT Margin%: 26.4%, increased from 24.6% in 9MFY23. Commenting on the performance, C.C. Paarthipan, Chairman said: "Consistency has always been a key area for our company and this Quarter is no different. The company delivered strong results, reporting Revenue from Operations of Rs 436 crore, resulting in a 17% YoY growth. Net Profit amounted to Rs 120 crore, reflecting a 23% YoY growth, with margins at 27%. Approval from Colombia’s INVIMA for our Caplin Steriles site will accelerate growth in newer markets like Mexico, Chile and Colombia, reinforcing our commitment to high regulatory standards and positioning us for success. We remain committed to driving sustainable growth with strong cashflows". Result PDF
Pharmaceuticals company Caplin Point Laboratories announced Q1FY24 results: Revenue for Q1FY24 grew by 13.1% YoY to Rs 407 crore Gross margin for Q1FY24 is at 54.8% EBITDA for Q1FY24 is Rs 139 crore; EBITDA margins at 34.0% Q1FY24 PAT is at Rs 104 crore up 20.8% YoY Cash and cash equivalents at Rs 808 crore as of June 30, 2023 Cash flow from operations at Rs 88 crore for Q1FY24; Capex for Q1FY24 is at Rs 51 crore; Free cash flow for the period was Rs 37 crore Basic EPS grew by 21% to Rs 13.62 in Q1FY24 against Rs 11.21 in Q1FY23 Receivable stood at 97 days Geographical breakup of sales: LATAM & ROW 88%, US 12% Commenting on the performance, C.C. Paarthipan, Chairman, said, “We are particularly pleased with the robust growth in our Latin America business, both in terms of revenue and profitability which also resulted in robust margins. The expansion of Softgel capacity at our CP-1 site has strengthened our position in this market, with a quick payback. Coming to the US, with a strong order book, we are optimistic about achieving 40-50% revenue growth in FY24. We aim to achieve this growth through strategic new product launches and by increasing our market share for existing products. Overall, we remain committed to driving sustainable growth and delivering value to all our stakeholders.” Result PDF